BFRI Stock Analysis: Buy, Sell, or Hold?
BFRI - Biofrontera Inc. Common Stock
$1.12
-0.01 (-0.88%)
▼
5d:
+2.75%
30d:
+36.75%
90d:
+14.29%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 21, 2026
21d
Get Alerted When BFRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BFRI shows positive signals but monitor for confirmation. Market pricing in 3.3% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BFRI shows positive signals but monitor for confirmation. Market pricing in 3.3% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BFRI is currently trading at $1.12, which is considered extended relative to its 30-day fair value range of $0.87 to $1.10. The stock's valuation (Forward PE: 8.0) is in line with its historical norms (7.3). At these levels, the market is pricing in 3.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BFRI is in a strong uptrend. Immediate support is located at $1.00, while resistance sits at $1.17.
Market Sentiment: BFRI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+435.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BFRI is in a strong uptrend. Immediate support is located at $1.00, while resistance sits at $1.17.
Market Sentiment: BFRI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+435.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.87 -
$1.10
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 435.7% below Wall St target ($6.00)
- NEUTRAL: Market pricing in 3.3% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$0.87 -
$1.10
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.00
Resistance Level
$1.17
Current Trend
Strong Uptrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.00
Wall Street Target
$6.00
(+435.7%)
Revenue Growth (YoY)
36.2%
Profit Margin
-25.3%
Valuation Premium vs History
+3.3% premium
PE vs Historical
8.0 vs 7.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.3%
(market-implied from PE analysis)
1-Year Target
$1.16
(+3%)
2-Year Target
$1.20
(+7%)
3-Year Target
$1.23
(+10%)
3-Yr Target (if PE normalizes)
(PE: 8→7)
PE COMPRESSION
$1.13
(+1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: April 29, 2026 2:38 AM ET
Data refreshes hourly during market hours. Next update: 3:38 AM
Data refreshes hourly during market hours. Next update: 3:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BFRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 60 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$150 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$94 | 58 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
